Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy

Gene Therapy

Volumn 17, Issue 12, 2010, Pages 1430-1441

  Cherry, T ^a,b   Longo, S L ^a   Tovar Spinoza, Z ^a   Post, D E ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

adenovirus; hypoxia; hypoxia inducible factor (HIF); interleukin 4; oncolytic; tumor

Indexed keywords

E1A PROTEIN; HYPOXIA INDUCIBLE FACTOR; ONCOLYTIC ADENOVIRUS; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INFILTRATION; CANCER REGRESSION; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; INTERLEUKIN-4; NEOPLASMS; ONCOLYTIC VIRUSES; TUMOR CELLS, CULTURED; VIRUS RELEASE; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 78650017203     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.100     Document Type: Article

References (61)

1. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-447.
2. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12: 853-859.
3. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
4. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421.
5. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
6. Weidemann A, Johnson RS. Biology of HIF-1α. Cell Death Differ 2008; 15: 621-627.
7. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008; 15: 628-634.
8. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 2005; 1755: 107-120.
9. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44.
10. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946-956.
11. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258.
12. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteo-lytic bone metastases of breast cancer. Cancer Res 2007; 67: 4157-4163.
13. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67: 563-572.
14. Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1: E83.
15. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000; 60: 4010-4015.
16. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-146.
17. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
18. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
19. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312.
20. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anti-cancer Ther 2006; 6: 697-708.
21. Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4: 1-14.
22. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42-58.
23. Post DE, Shim H, Toussaint-Smith E, Van Meir EG. Cancer scene investigation: how a cold virus became a tumor killer. Future Oncol 2005; 1: 247-258.
24. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
25. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478.
26. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998; 72: 9479-9490.
27. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001; 8: 1801-1807.
28. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22: 2065-2072.
29. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10: 8603-8612.
30. Okada H, Kuwashima N. Gene therapy and biologic therapy with interleukin-4. Curr Gene Ther 2002; 2: 437-450.
31. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007; 67: 6872-6881.
32. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996; 93: 12969-12973.
33. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG et al. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 2006; 13: 242-252.
34. Gallimore PH, Turnell AS. Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 2001; 20: 7824-7835.
35. Kramer PR, Stringer JR, Sinden RR. Stability of an inverted repeat in a human fibrosarcoma cell. Nucleic Acids Res 1996; 24: 4234-4241.
36. Lobachev KS, Shor BM, Tran HT, Taylor W, Keen JD, Resnick MA et al. Factors affecting inverted repeat stimulation of recombination and deletion in Saccharomyces cerevisiae. Genetics 1998; 148: 1507-1524.
37. Bissler JJ. DNA inverted repeats and human disease. Front Biosci 1998; 3: d408-d418.
38. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75-111.
39. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306.
40. Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7K/gp19K region. Gene Ther 2001; 8: 1123-1131.
41. Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther 2001; 8: 1132-1141.
42. Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther 2001; 8: 1142-1148.
43. Bortolanza S, Bunuales M, Alzuguren P, Lamas O, Aldabe R, Prieto J et al. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther 2009; 16: 703-712.
44. Kasper LH, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J 2005; 24: 3846-3858.
45. Lisy K, Peet DJ. Turn me on: regulating HIF transcriptional activity. Cell Death Differ 2008; 15: 642-649.
46. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004; 10: 938-949.
47. Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 2005; 12: 902-910.
48. Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S et al. Hypoxia reduces adenoviral replication in cancer cells by down-regulation of viral protein expression. Gene Ther 2005; 12: 911-917.
49. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139-146.
50. Hallden G, Hill R, Wang Y, Anand A, Liu TC, Lemoine NR et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003; 8: 412-424.
51. Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocom-petent tumor models. Nat Biotechnol 2003; 21: 1328-1335.
52. Guo W, Zhu H, Zhang L, Davis J, Teraishi F, Roth JA et al. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 2006; 13: 82-90.
53. Stanford MM, McFadden G. The 'supervirus'? Lessons from IL-4-expressing poxviruses. Trends Immunol 2005; 26: 339-345.
54. Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, Parker RA et al. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol 1997; 71: 8672-8677.
55. Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol 1996; 70: 5230-5235.
56. Benedetti S, Bruzzone MG, Pollo B, Dimeco F, Magrassi L, Pirola B et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res 1999; 59: 645-652.
57. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst 1999; 91: 438-445.
58. Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17: 614-622.
59. Toth K, Spencer JF, Wold WS. Immunocompetent, semi-permissive cotton rat tumor model for the evaluation of oncolytic adenoviruses. Methods Mol Med 2007; 130: 157-168.
60. Thomas MA, Spencer JF, Wold WS. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169-183.
61. ARF PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.